Search academic texts

Information × Registration Number 0205U004020, 0101U006113 , R & D reports Title A new drug Blasten in the regimes of complex treatment breast cancer patients popup.stage_title Head Chekhun V.F., Registration Date 23-02-2005 Organization R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology popup.description2 The chemotherapy and radiotherapy are considerable part of treatment of cancer patient. Simultaneously with antitumor effect its display also side toxic effects at immune, blood and other systems of human body. This side negative effects result in decrease in quality of life of cancer patients, interfere with their active social life and also to decrease of antitumor defence and tumor progression. Therefore the development of support therapy has very important. This therapy should prevent, lower or eliminate of side effect of chemo- and/or radiotherapy, to increase of tumor drug sensitivity. It is desirable, that support therapy rendered some antitumor and antimetastatic effect. The immunobiotechnological drugs that increase of cancer patients treatment effect are promising for their use as support therapy drugs. These drugs are characterized by multilateral positive influences on an human body, to improve of function of its immune and other system. In preliminary researches have been shown that probiotic Lactobacillus strains are promising for creation of support therapy drugs. The purpose of our project was to increase efficiency of cancer patient complex treatment by development of new complex treatment with new preparation from Lactobaciilus Delbrueckii blasten. Proceeding from the purpose of our project the following problems have been put: - to study of dependence probiotic cultures strain Lactobacillus immunogenocity and growth conditions for development of probiotic drugs production cycle immunobiological properties; - to investigate biological activity of different series of substance blasten and to select series of a substance for creation of a preparation; - to investigate stability of a preparation blasten and to define conditions of its storage; - to investigate protective properties of blasten at different regimens in relation to chemotherapy; - to investigate the antitumor activity of blasten at experiment; - to study efficiency of application of a preparation blasten at complex treatment of cancer patients. Object of research: probiotic strain Lactobacillus murinus LE cells; mouse lymphoma L1210 cells; imbredded white mice and mice of 57Bl/6 line; Wistar rats transfected Gueren carcinoma initial strain, substrains doxorubicin and cisplatin resistance. In research the healthy women, breast cancer patients and patients with fibroadenoma have been involved. Methods of research: clinical, biochemical, immunological, microbiological, statistical. Results. Immunobiological properties of different kinds of lactic bacteria are characterized. Conditions of reception of components of cellular walls lactobacillus with immunomodulator activity are developed. It is revealed, that culture conditions significant influence on immunobiological activity of different lactobacillus strain. It is possibility to change of activity through regulation of influence on structural components of cellsand the directed management of biochemical features of structure of cellular walls probiotic cultures of lactic bacteria. Requirements on selection of probiotic microorganisms for production of probiotic drugs have been changed. Amendments to the specifications and technical documentation on probiotic production on the basis of cultures L. rhamnosus LB3 and L. murinus LE are prepared to the Center of immunobiotechnological preparations of the Ministry of Health of Ukraine. Firstly in Ukraine in laboratory manufacture conditions the "know-how" of a preparation Blasten is reproduced on the basis of a substance blasten. It is shown, that the preparation Blasten made of a substance from the faculty of industrial biotechnology of the Kiev national polytechnical university possesses high stability and corresponds to requirements of pharmacological article. It is experimentally shown that blasten increases a perapheral blood leukocyte level as granulocytes also agranulocytes. Blasten activates system of complement and causes leukocyte reaction, and also stimulates proliferation of granulo- agranylocytes predecessors. Blasten protects a bone marrow and internal organs from cytotoxic anticancer drugs (doxorubicine, cisplatine, cyclophosphamide, fluorouracil) and renders weak antineoplastic and antimetastatic properties. It is shown, that complex treatment with blasten increases cancer patients II-III stages 5-years survival rate on 13 % (р <0,05). Keywords: Lactobacillus, probiotic, controlled synthesis, immunomodulator, peptidoglycan, cytostatic, protective hemotoxic action Product Description popup.authors popup.nrat_date 2020-04-02 Close